Patents by Inventor Simona Volpi

Simona Volpi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20150225794
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 13, 2015
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20150225795
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 23, 2015
    Publication date: August 13, 2015
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
    Patent number: 9080214
    Abstract: Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction.
    Type: Grant
    Filed: May 17, 2008
    Date of Patent: July 14, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9074256
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9074254
    Abstract: The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9074255
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Method of predicting a predisposition to QT prolongation
    Patent number: 9072742
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Grant
    Filed: April 5, 2010
    Date of Patent: July 7, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • Antipsychotic treatment based on DRD2 or ANKK1 SNP genotype
    Patent number: 9057104
    Abstract: The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.
    Type: Grant
    Filed: May 15, 2010
    Date of Patent: June 16, 2015
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi
  • Prediction of QT prolongation based on SNP genotype
    Patent number: 8652776
    Abstract: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: February 18, 2014
    Assignee: Vanda Pharmaceuticals, Inc.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20140039008
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: October 2, 2013
    Publication date: February 6, 2014
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20120059035
    Abstract: The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: March 8, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20120058201
    Abstract: The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval- prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: March 8, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • ANTIPSYCHOTIC TREATMENT BASED ON DRD2 OR ANKK1 SNP GENOTYPE
    Publication number: 20120053207
    Abstract: The present invention relates to the treatment of an individual with an antipsychotic based on individual's genotype at one or more single nucleotide polymorphism (SNP) associated with the dopamine receptor D2 (DRD2) and/or ankyrin repeat and kinase domain containing 1 (ANKK1) genes.
    Type: Application
    Filed: May 15, 2010
    Publication date: March 1, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20120035215
    Abstract: The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: April 5, 2010
    Publication date: February 9, 2012
    Applicant: VANDA PHARMACEUTICALS, INC.
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele
  • GENETIC MARKERS FOR EFFICACY OF ILOPERIDONE IN THE TREATMENT OF PSYCHOTIC SYMPTOMS
    Publication number: 20110021566
    Abstract: Methods for predicting whether iloperidone will be efficacious in treating a psychotic symptom in an individual, based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci are described, as are methods for treating an individual based on such prediction.
    Type: Application
    Filed: May 17, 2008
    Publication date: January 27, 2011
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Mihael H. Polymeropoulos
  • PREDICTION OF QT PROLONGATION BASED ON SNP GENOTYPE
    Publication number: 20100249188
    Abstract: The present invention relates to the prediction of QT prolongation following administration of a compound capable of increasing an individual's QT interval based on the individual's genotype at one or more single nucleotide polymorphism (SNP) loci and to the treatment of a patient based on such prediction.
    Type: Application
    Filed: September 10, 2008
    Publication date: September 30, 2010
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • METHOD OF PREDICTING A PREDISPOSITION TO QT PROLONGATION
    Publication number: 20100226858
    Abstract: The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
    Type: Application
    Filed: March 28, 2008
    Publication date: September 9, 2010
    Inventors: Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
  • METHODS FOR THE ADMINISTRATION OF ILOPERIDONE
    Publication number: 20100063093
    Abstract: The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
    Type: Application
    Filed: September 10, 2008
    Publication date: March 11, 2010
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
  • Cross-Reference To Related Applications
    Publication number: 20080033053
    Abstract: Adamantane and other agents with similar effects on gene expression are useful in the treatment or prevention of ocular disorders.
    Type: Application
    Filed: July 22, 2005
    Publication date: February 7, 2008
    Inventors: Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi